Evidence map›Paper›PMID 40767921›Full record

ArticleJournal of molecular histology2025

Sorghum bicolor supplement attenuates rotenone-induced behavioral derangements in rats through neuroprotective mechanisms and modulation of tyrosine hydroxylase and α-synuclein/NF-kB immunopositive cells expressions.

Olajide Saheed Annafi, Paul Ademola Adeleke, Love Enebeli, Abayomi Mayowa Ajayi, Benneth Ben-Azu, Olajuwon Okubena, Solomon Umukoro

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Naringin Reverses Chronic Stress-Induced Cognitive Deficits and Enhances Hippocampal Neuroplasticity in Mice.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Olajide Saheed AnnafiDepartment of Pharmacology and Therapeutics, College of Health Sciences, Osun State University, Osogbo, Osun State, Nigeria.ORCID http://orcid.org/0009-0001-3005-1293
Paul Ademola AdelekeNeuropharmacology Unit, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Sango-Ojo Road, Ibadan, Oyo State, Nigeria.ORCID http://orcid.org/0000-0002-8466-2807
Love EnebeliNeuropharmacology Unit, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Sango-Ojo Road, Ibadan, Oyo State, Nigeria.ORCID http://orcid.org/0000-0002-6385-8712
Abayomi Mayowa AjayiNeuropharmacology Unit, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Sango-Ojo Road, Ibadan, Oyo State, Nigeria.ORCID http://orcid.org/0000-0001-6586-0421
Benneth Ben-AzuDELSU Joint Canada-Israel Neuroscience and Biopsychiatry Laboratory, Department of Pharmacology, Faculty of Basic Medical Sciences, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.ORCID http://orcid.org/0000-0003-3569-3575
Olajuwon OkubenaNeuropharmacology Unit, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Sango-Ojo Road, Ibadan, Oyo State, Nigeria.ORCID http://orcid.org/0000-0001-9174-8169
Solomon UmukoroNeuropharmacology Unit, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Sango-Ojo Road, Ibadan, Oyo State, Nigeria. umusolo@yahoo.com.ORCID http://orcid.org/0000-0003-2065-5111

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The loss of dopamine due to progressive degeneration of dopaminergic neurons is the primary cause of neurobehavioral disturbances in Parkinson's disease (PD). Current research focuses on developing neuroprotective agents that can halt the progressive degeneration of dopaminergic neurons in PD, as its cure remains elusive. Several herbal products, including extracts from Sorghum bicolor, which possess neuroprotective properties, are being investigated as potential agents for PD. In this study, we investigated the effects of Sorghum bicolor supplement (SbS) on rotenone-induced neurobehavioral and neuropathological derangements in male Wistar rats. The rats were distributed into six groups (n = 7): group 1 received vehicle (control), group 2 also received vehicle (rotenone-control), group 3-5 had SbS (50, 100 and 200 mg/kg) while group 6 received Levodopa-carbidopa (10 mg/kg), orally for 28 days. In addition, group 2-6 also received intraperitoneal injections of rotenone (2.5 mg/kg), 30 min after each treatment, on alternate days for 28 days. Neurobehavioral functions were evaluated on day 28 using a hanging wire test for motor function, Y-maze for memory, and sucrose splash test for depression. The rats' brain contents of myeloperoxidase, acetylcholinesterase, dopamine, tyrosine hydroxylase (TH), caspase-3, nuclear factor kappa B (NF-κB), and α-synuclein were determined. Histomorphological changes and dendritic arborizations were assessed. The SbS attenuates motor deficit, memory dysfunction, and depression-like effects in rotenone-treated rats. The supplement modulates myeloperoxidase, acetylcholinesterase, caspase-3, TH, NF-κB, and α-synuclein contents in rotenone-treated rats. Rotenone-induced histomorphological alterations, loss of neuronal cell viability, and dendritic arbors were abrogated by SbS. The findings suggest that SbS attenuates rotenone-induced behavioral deficits in rats through neuroprotective mechanisms and modulation of TH and α-synuclein/NF-kB immunopositive cell expressions.

Indexed as

alpha-SynucleinBehavior, AnimalDietary SupplementsNeuroprotective AgentsNF-kappa BPlant ExtractsRotenoneSorghumTyrosine 3-MonooxygenaseAnimalsBrainDopaminergic NeuronsMaleRatsRats, Wistaralpha-SynucleinNeuroprotective AgentsNF-kappa BPlant ExtractsRotenoneTyrosine 3-MonooxygenaseNeuroprotectionParkinsonian-like featureRotenoneSorghum bicolor supplement

Identifiers

PMID40767921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.